PCSK9 and carbohydrate metabolism: A double-edged sword.
about
The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis.SGLT2 inhibitors: are they safe?Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies.Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.
P2860
PCSK9 and carbohydrate metabolism: A double-edged sword.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
PCSK9 and carbohydrate metabolism: A double-edged sword.
@en
PCSK9 and carbohydrate metabolism: A double-edged sword.
@nl
type
label
PCSK9 and carbohydrate metabolism: A double-edged sword.
@en
PCSK9 and carbohydrate metabolism: A double-edged sword.
@nl
prefLabel
PCSK9 and carbohydrate metabolism: A double-edged sword.
@en
PCSK9 and carbohydrate metabolism: A double-edged sword.
@nl
P2093
P2860
P356
P1476
PCSK9 and carbohydrate metabolism: A double-edged sword.
@en
P2093
Eleni Pappa
Moses S Elisaf
Sebastian Filippas-Ntekouan
Thalia Panagiotopoulou
Theodosios D Filippatos
Vasilios Tsimihodimos
P2860
P304
P356
10.4239/WJD.V8.I7.311
P577
2017-07-01T00:00:00Z